Consumer focus shifts from physical to mental health

The pandemic has intensified a rise in depression, anxiety and distress and, while immunity remains a key focus, there has been a shift in the past two years from physical to mental health. This is according to GameChanger 2022, a report published by brand-building agency Healthy Marketing Team. Increasingly aware of the role of good mental balance for the body’s response to any health threat and the role played by the microbiome, consumers are moving away from the single hero ingredient for immunity to a more holistic approach that also includes stress relieving and mood boosting components. HMT founder Peter Wennström writes: “You must understand how to connect to today’s consumers not only with physical benefits and rational claims but also with emotional benefits … The value chain starts in the mind of the consumer — more so now than ever before.”

Comment from CHC.Newsflash Deputy Editor, Kirsten McEwan: The after-effects of pandemic-related lockdowns, worries and upheavals to our lives have become ever apparent and the rise in mental health issues is perhaps unsurprising. A study published in The BMJ (16th February 2022) highlights a further cause for concern about mental wellbeing in the post-Covid era. Researchers from the VA St Louis Healthcare System analysed data from the US Dept of Veterans Affairs database for 153,848 people who tested positive for Covid-19 between March 2020-January 2021; the data was matched to that from 5.6mn+ people without Covid and 5.8mn+ people pre-pandemic. Those with Covid had a 60% increased risk of a mental health diagnosis or prescription in the year following infection vs controls. Covid infection was associated with sleep disorders, depressive disorders, neurocognitive decline and substance use disorders. The researchers point out that the study included mostly older white men and the findings may not apply to other groups, but marketers may want to take note of this more specific target market.

^{Sedatives & sleep aids was one of the Top 5 most active CHC subcategories for new product development in 2021. Source: CHC New Products Tracker.}

Nicholas Hall’s Touchpoints: Mental health has been a growth sector of the global CHC market for at least 5 years. Sleep aids & sedatives have accumulated sales of about US$3bn, with a 7% CAGR since 2016, but growth accelerated even faster during the pandemic to 13%. More dynamic still was herbal memory & brain health, which most recently grew by 18% to US$1bn, with a 5-year CAGR of 10%.

Consumer demand is strong for all the reasons outlined in this week’s lead story and in my colleague Kirsten McEwan’s commentary. Yet I sense that many of the brands sold in the sector are deficient in some way – either a lack of excitement, weak claims or the formulations are old and with little scientific support. Prevagen from Quincy Bioscience is a standout in memory & brain health, but its clinical studies have been roundly contested by the authorities. Quincy always fights back, seems to win these arguments, continues to have very high growth and is looking to take a better than one-third global market share even though it is sold only in the USA.

Sleep aids & sedatives are much more fragmented and, although it is growing well, brand leader ZzzQuil (P&G) takes only a 6% global market share. It seems to me that the leading players in this sector, and new entrants, need to redefine their positioning and claims, and invest in more product development and clinical trials, if they are to take full advantage of abundant unmet consumer demand.

Put your brands into the spotlight at The Nicholas Hall CHC Marketing Awards 2022, which will take place during our 32nd European CHC Conference & Action Workshop. Entry submission is open until 1 April! For more information about entry criteria, or more details about the meeting, which will take place on 4-6 May 2022 in Athens, please contact elizabeth.bernos@NicholasHall.com.

CRN survey shows sharp rise in US VMS usage in 2021

The Council for Responsible Nutrition has revealed initial findings from its 2021 Consumer Survey on Dietary Supplements, which was fielded by Ipsos in August and involved 3,089 adults aged 18+ years. Vitamin D usage has significantly increased (52% vs 42% in 2020), as has zinc (22% vs 15%) and vitamin C (40% vs 35%); all could be helpful for combatting Covid-19 and boosting overall immunity. Further, 50% of supplement users report a change to their supplement routine since the start of the pandemic; 55% of those indicated that this includes adding new supplements to their existing routine.

ClearCut Analytics Director of Sales Jake Bernstein told attendees of the CRN Annual Conference, where the findings were unveiled, that dietary supplement sales on Amazon have risen by 43% and predicted that 25% of sales will be purchased online by 2024. Ashwagandha and collagen were the Amazon star performers.

Nicholas Hall’s Touchpoints: This important research is another building block in helping us to understand how consumer attitudes have changed during the Covid-19 lockdown. As CRN’s Brian Wommack comments: “With 80% of Americans using supplements, these products are now mainstream and broadly accepted by the public. Just as important, 79% of Americans believe the dietary supplement industry is trustworthy, a jump of 5% from 2020.” This data and these comments will be taken into account in our ongoing evaluation of whether the CHC market is moving back to treatment and reversing the recent trend towards prevention & immunity. 

However this turns out, one clear learning emerges: consumer trends move slowly, accelerated only by mega-happenings such as the recent pandemic. By comparison, fashions in the pharmaceutical industry, including its CHC daughter, are highly volatile. 

Our Innovation in CHC 2021 report assesses 10 major trending ingredients, with a strong focus on VMS. Drawing from CHC New Products Tracker, this report also explores trends in NPD activity by company, reviews the best CHC innovations and much more. For more information or to order your copy, please contact melissa.lee@NicholasHall.com.

Three surveys assess Covid’s impact on our health

Three surveys published in recent weeks have gauged the impact of the Covid-19 pandemic on our dietary and supplement habits, our use of technology and our mental health. Here we present a quick survey of the findings in all three studies.

According to a survey of 13,000 people in 24 countries conducted by OnePoll on behalf of the Council for Responsible Nutrition and Herbalife Nutrition, eight in 10 US citizens believe their health is “work in progress”. Some 89% of respondents worldwide are taking steps to improve their health, with 81% reporting that the pandemic helped to kickstart them.

Vitamins and supplements are a priority for many; when asked about how their health goals have changed, half said they are more focused on eating healthier, including supplementing their diet with vitamins & minerals, with the average respondent spending around US$286 each year. However, only 69% reported feeling knowledgeable about the health benefits and 77% would like to know more. Some 30% are most likely to get information about vitamins and supplements from internet searches, media and social media, followed by consulting with their doctor (27%).

^{Source: OnePoll / Herbalife / CRN}

According to a survey from Saudi-based cultural institute Ithra, 91% of people globally are spending more time online because of the pandemic, and 44% are worried about the impact of internet and smartphone use on their health. Respondents in Sub-Saharan Africa and South Asia appear most worried, with 74% and 56% respectively fearing the negative consequences of the internet on wellbeing vs 27% in Europe and Central Asia. Consistent with their increased use of devices, younger people are experiencing more physical symptoms than their elders, with 50% of Gen Z respondents complaining of tiredness, poor sleep and headaches.

And, finally, a study published in BJPsych Open revealed the mental health of adults aged over 50 has been significantly compromised by Covid-19. University of Surrey researchers analysed data in 5,331 participants from the English Longitudinal Study of Ageing. Self-reported depression in June and July 2020 were compared with baseline data from 2-3 years prior. Some 26% met the criteria for clinical depression during the pandemic vs 14% in previous years. Women were found to be at a much higher risk, as well as people living alone and those with long-term health conditions. Women living in an urban environment showed a larger increase in depression symptoms than those in more rural areas. The research also found that individuals at the younger end of the 50+ population suffered more.

In just 2 weeks, you can join Nicholas and a panel of industry experts at our North American e-Conference 2021. Sponsored by Catalent, you can look forward to hearing about consumer shopping behaviours, the non-prescription imperative, natural channel retail world and much more. To register, or for further details, please contact elizabeth.bernos@NicholasHall.com.

Seasonal respiratory viruses re-emerge post-Covid

Recent reports from the UK and USA suggest a severe cold & flu season may be in store during winter 2021-22. With lockdown restrictions, increased hygiene measures and social distancing in force for over a year to reduce the risk of contracting Covid-19, the incidence of common respiratory viruses has been very low. However, with the lack of exposure to illnesses (especially among young children), many of us have not built up antibodies and as a result our immune systems may have been inadvertently weakened.

This has prompted warnings of a potential surge in influenza as measures are lifted; data released this week by the UK’s Office of National Statistics show that in the week ending 11th June, 84 death certificates issued in England & Wales mentioned Covid, while 1,163 deaths involving flu and pneumonia were registered. Additionally, a recent study by the Houston Methodist Research Institute shows the rapid re-emergence of seasonal respiratory viruses following the relaxing of Covid-19 restrictions in Texas in March 2021.

Source: Houston Methodist Research Institute

This trend was also reported in a recent article in STAT, in which Trevor Bedford, a computational biologist who monitors which viruses are circulating via the Nextstrain service, was quoted as saying: “Just in the last month [May 2021] or so we’ve started to pick up small amounts of seasonal coronavirus, RSV, metapneumovirus, etc. It’s the first time since April 2020 where we’re starting to see other things circulating.”

There is particular concern that by the time universities, colleges, schools and nurseries reopen this autumn across the northern hemisphere, there will be perfect conditions for high transmission of seasonal respiratory viruses, particularly RSV (respiratory syncytial virus). Andrew Pavia, Chief of the Division of Pediatric Infectious Diseases at the University of Utah, warned: “There will be two years’ worth of kids who are naïve to RSV, instead of one birth cohort. That could be fertile ground for a big RSV year.”

Epidemiologist Professor Neil Ferguson of Imperial College, a member of the UK Government’s Scientific Advisory Group for Emergencies, said in a BBC interview that we must be prepared for a potentially “quite significant” flu epidemic and increased hospitalisations this winter. To help save National Health Service resources, researchers are investigating whether seasonal flu jabs and a Covid vaccine can be administered at the same time.

We are pleased to announce that our Eye Health report is now published and available to order! You can review case studies of key brands, NPD activity and much more. Plus, ensure you have registered for the free webinar on 30 June here to discuss the topline findings. For more information, please contact melissa.lee@NicholasHall.com.

Stada Health Report 2021

According to the third Stada Health Report, a representative survey of 30,000 participants in 15 European countries, 29% have suffered from increased levels of anxiety during the pandemic, while 25% are troubled by stress and inner restlessness and 15% have reported sleep disturbances. Some 52% of respondents are more affected by the lack of personal contact with family & friends than fear of Covid infection (42%), while almost 1 in 3 worries about the financial and work-related repercussions.

However, 70% of Europeans have been willing to invest more in their own health. For 73%, their doctor is the first point of call for all health-related issues, with pharmacists and scientists also highly trusted (60% each). Despite a 14 percentage-point increase in people purchasing medication online, 43% stay loyal to community pharmacies, 13% of which specifically single out their local branch. Europeans care more about brand names and what is associated with them (38%) rather than sustainable & environmentally-friendly packaging (25%) or whether a product was made in Europe (20%).

In the report, Stada asks the question, “With an increased interest in and an aspiration to healthy living, how did people in Europe procure information on these topics? The short answer is: The internet. 54% of Europeans have increased their online searches for health-related information compared to previous years.” However, this spike in online health searches and literacy has not automatically translated into European consumers looking to bypass their pharmacist when acquiring medication, or information about it. According to Stada’s survey, only 14% of Europeans have ordered more OTC medicines via online pharmacies post-pandemic, and 43% flat out refuse to order them online at all. Despite the ever increasing number of e-Commerce platforms and other channels for obtaining medicines online, community pharmacies are still Europe’s first choice for OTCs.

Nicholas Hall’s Touchpoints: The Stada report quoted above is further evidence that increased levels of stress and anxiety, and disrupted sleep, are by-products of Covid. Insomnia was already considered a pandemic in the Western world by the World Health Organization; and sleep, stress and mood have joined immunity and disinfection as categories with rocketing sales in the past two years … The theme continues in the latest Gallup survey, which notes the high incidence of “worry, stress, anger and sadness among employees worldwide”. It seems that substantial numbers of office workers are refusing to go back to work in the traditional way and are insisting on continuing to work from home … This localisation of labour will almost certainly change our concept of shopping and could benefit independent neighbourhood pharmacies, giving a whole new meaning to the concept of Pharmacy Point-of-Care. It’s too soon to draw definite conclusions, but consumer healthcare companies would do well to re-examine their sales force objectives. One of the most successful modules of the CHC Training Academy is “Winning in Pharmacy”, and I can see this being even more popular as we come out of the Covid lockdown.

To find out more about Winning in Pharmacy, or the offerings from The CHC Training Academy, please contact maricar.montero@NicholasHall.com. The CHC Training Academy can also work with you to develop your own in-house customised training programmes according to your specific strategic needs.

AESGP 57th Annual Meeting Review

From CHC Insight Europe Editor, Sarah Carter, who reports that the AESGP sees a brilliant future for self-care, but that the industry must continue to adapt.

Focusing on self-care in times of the pandemic and beyond, the 57th AESGP Annual Meeting discussed opportunities, challenges and lessons learnt. While the pandemic has caused significant disruption and altered behaviours, priorities and shopping habits, it has driven a surge in interest in self-care, with consumers increasingly looking to stay well and prevent illness. Birgit Schuhbauer, who has just been re-elected as AESGP President for the next two years, stated that the CHC industry has a “brilliant future ahead of us”.

The CHC industry has had to adapt to this changing landscape, although a number of speakers stressed that it must do so at a quicker pace as technology and evolving consumer demands continue to disrupt the traditional self-care model. AESGP Director General Jurate Svarcaite concluded that there is no going back to the old model, stressing that the “new normal” requires collaboration and partnership.

Speakers also touched upon the infodemic and the increasing consumer appetite for instant information, which European Medicines Agency Executive Director Emer Cooke said was difficult to manage when you try to have a “sound scientific basis for what you communicate”. However, the worrying spread of misinformation and disinformation means that increased and better communication is vital.

The Annual Meeting coincided with the long-awaited implementation of the new EU Medical Device Regulation; participants shared their excitement and optimism at the development and celebrated how much work had been done, but were keen to stress there remains a way to go, particularly in terms of harmonisation across Europe and the capacity of notified bodies.

There is still time to register for our free webinar on 30 June discussing the topline conclusions from our upcoming report on Eye Health! With no purchase necessary, you can register directly for the webinar here. For more information, please contact melissa.lee@NicholasHall.com.

European e-Conference report 2021

In this week’s blog, we highlight the key takeaways from our recent European e-Conference and take a closer look at one of the slides from Nicholas Hall’s Global Trends presentation, looking at the fastest-growing brands in consumer healthcare over the past five years.

Nicholas Hall Writes: 100 delegates from around the world joined us in late April for our first-ever e-Conference, and many more are expected to listen to the recording. The conference reviewed global and European trends in the consumer healthcare market, the impact of Covid, changing consumer attitudes and the omnichannel shopper journey, the digital revolution and our forecasts for the future. These and many other topics were covered under the banner of “A Glimpse into the New Normal”.

There is no denying that “immunity” is the biggest buzzword in consumer healthcare at the moment, and has produced some amazing results. We’ve just completed an analysis of the new DB6 data, looking at the fastest-growing brands over the past five years. Just to be clear, this is drawn from the 200 biggest brands and excludes those specifically from China, which are very largely formulated with traditional Chinese medicine. Sambucol, a brand I love dearly and have used for 20 years, shows up as the second fastest growing brand. Only Biofreeze (to be acquired by Reckitt in a deal expected to complete in Q2 2021) has grown faster during this period.

_{Source: Nicholas Hall’s DB6 database. All values US$mn at MSP.}

CHC Insight Europe Editor Sarah Carter and Researcher / Writer Nathalie Corbett filed this report summarising various highlights from our European e-Conference:

• There is an increased consumer focus on prevention, not just in terms of avoiding Covid-19, but also awareness that people with better overall health have better lifestyle outcomes. Many consumers are no longer looking for treatment, but instead seek to safeguard their future health.

• During the pandemic, the health consumer has evolved from patient to “consum’actor”, who uses their purchasing power to protect the values and causes they believe in.

• The consumer is in control of our industry and we need to deliver on their expectations. The best medicine is a consumer who is informed, empowered and inspired.

• The way consumers shop has been severely disrupted and perhaps irrevocably altered by the pandemic. The CHC industry must respond with agility in order to successfully compete in this omnichannel landscape.

• Consumers cross these different channels in a way that’s seamless, with lines blurring between communication, point of purchase, advertising, etc.

• It’s all about the data – get this data culture deeply embedded at all levels of your organisation. It’s also about the right data, and not being inundated with data that isn’t useful. Identify the relevant KPIs and target those.

• Tech and Big Data can help us gather insights and use these to deliver relevant business developments and product innovations. Consumers themselves are increasingly generating a wealth of data, including via self-monitoring devices.

• Online can offer opportunities that offline cannot, even when it comes to personal advice. Digital interactions are sometimes preferable vs crowded stores / time constraints.

• But pharmacies still account for 76% of purchases, and have a superb chance to fight back and regain market share provided they collect new insights into their customers’ shopping journeys.

• We should no longer refer to e-commerce, but rather e-life. Platforms like Amazon are increasingly media hubs rather than just online stores.

• Brand building is more important than ever as consumers adapt to the New Normal. We must be present and relevant and focus on creating an emotional bond with the consumer, a traditionally weak area.

• There can be no return to old strategies and the old way of doing business. It is time for new strategies and New Paradigms.

We hope you enjoyed our European e-Conference 2021! If you couldn’t attend, you can still purchase a recording of the meeting by contacting elizabeth.bernos@NicholasHall.com. Immunity & other Growth Drivers will be the focus of our next round of regional hot topic webinars. Starting with a focus on Asia-Pacific on 19 May, on the Americas on 23 June and concluding with Europe on 21 July. Please contact elizabeth.bernos@NicholasHall.com to find out more.

Nasal sanitisers niche opens up post-Covid

One of the fast-emerging OTC niches in the CCA category is oral & nasal sanitisers, with several notable innovations in 2020 and 2021, including two more nasal sanitiser launches announced recently.

Australian-based Starpharma’s Viraleze nasal spray will become available online in the UK this week ahead of a retail rollout in April 2021, under an exclusive sales & distribution agreement with the retail chain, LloydsPharmacy (McKesson). This will be the product’s first appearance in Europe, although a regional launch is expected soon following its registration in the European Economic Area in February.

Comment from CHC Insight Managing Editor, Chris Allan: Viraleze contains the same antiviral ingredient (SPL7013 / astodrimer sodium) that features in Starpharma’s VivaGel products. Its powerful claim to deactivate “>99.9% of Sars-CoV-2 within one minute” is likely to attract wider media interest given the continuing national focus on the pandemic, and LloydsPharmacy has committed to “significant” marketing investment.

Separately, in Israel, SaNOtize has received interim approval to sell its nitric oxide nasal spray (NONS) in pharmacies. NONS protects users from viruses that enter the body through the upper nasal pathways. Local manufacturing under the brand name Enovid has begun in partnership with Nextar Chempharma Solutions and the spray is expected to appear on pharmacy shelves by the summer.

Meanwhile, in New Zealand the Ministry of Health denied claims by the Canadian-based biotech company that Enovid had been cleared for immediate OTC sale. Newshub quotes a MoH spokesperson: “Based on the therapeutic claims made for the product, its claimed mode of action and the nitric oxide ingredient, Enovid nasal spray would be a prescription medicine under New Zealand law (Medicines Act 1981) … Medsafe has received no applications for approval of this product for sale, supply or use in New Zealand.”

Comment: SaNOtize and Ashford & St Peter’s Hospitals NHS Foundation Trust in the UK recently announced results of clinical trials indicating that NONS represents a safe and effective antiviral treatment that could prevent the transmission of Covid-19, shorten its course and reduce the severity of symptoms and damage in those already infected.

Oral & nasal sanitisers is one of the delivery formats trends covered in our new Innovation in CHC 2021: NPD & Launch Activity under the Spotlight report. Seize the last chance to save GB£1,350 when you pre-order this forthcoming report before 31st March. To review the table of contents or pre-order your copy, please contact melissa.lee@NicholasHall.com

Historically slow cough, cold & flu season

Now that four (P&G, J&J, GSK and Sanofi) of the world’s Top 6 consumer healthcare marketers have reported their latest quarterly results, two of the key takeaways are that 1) industry growth has proven very resilient in the face of the challenges posed by the pandemic, and 2) we are in the middle of an historically slow cough, cold & flu season in 2020-21, and CHC marketers with portfolios that skew heavily towards CCA products will continue to feel the impact of this trend on overall growth.

Figures from the WHO’s FluNet service show the quasi-total wipeout of flu at a global level. Despite some signs of very low levels of flu circulation in certain regions tracked by WHO, including Africa and the Western Pacific, the overall picture at a global level is stark, with an almost complete drop-off in global infections since Q1 2020. The data shown in the WHO chart below are provided remotely by National Influenza Centres (NICs) of the Global Influenza Surveillance and Response System (GISRS) and other national influenza reference laboratories collaborating actively with GISRS, or are uploaded from WHO regional databases.

Source: FluNet (www.who.int/flunet), GISRS

This trend is backed up by recent reports at a country level too. According to data obtained by The Times newspaper, UK flu cases are down by 95%; in the second week of January – the peak of the season – the number of reported influenza-like illnesses was 1.1 per 100,000 people vs a 5-year average rate of 27. This reflects similar trends in many other countries, including USA. While a billion people typically get flu globally each year, “much less than a tenth” of that figure will do so, according to leading expert John McCauley. There are a number of theories for the decline; lockdown restrictions, social distancing and the wearing of masks, and an increased focus on good hygiene practices have helped to prevent Covid, but also reduce the spread of other contagious illnesses. A major fall in international travel has curbed infections, while there has also been a huge take-up of the influenza vaccine. Meanwhile, some experts believe the spread of Sars-CoV-2 may have raised immunity against other viruses.

Nicholas Hall said: “Before Covid, we thought we knew the dynamics of consumer healthcare very well. I’ve given endless presentations quoting the three practical drivers of demand: Switch, the Emerging Markets and very importantly Cold & Flu pandemics. It’s fair to say that, without Covid, we would by now be lamenting a year of poor CHC sales. The actuality is that, with the exception of Voltaren Arthritis Pain and Differin in USA, there have been no significant switches in the past 3-4 years. The Emerging Markets still deliver, of course, but not at the stellar levels of the recent past; and we would by now be reading of the low impact on sales of the cough, cold & flu season.”

Explore the impact of lockdown on cases of cold & flu, and what the implications may be for CHC medicines, in our recently published Cough, Cold & Allergy report. For more information, or to order your copy, please contact melissa.lee@NicholasHall.com.

Q4 2020 results round-up

Early signs from quarterly results published last week by CHC marketers, with both a global (P&G) and European (Galenica, Alliance Pharma) focus, indicate that consumer healthcare growth continued to be robust in the final quarter of 2020. There are some warning signs on the dashboard, notably P&G’s reference to a “historically slow start” to the cough, cold & flu season – which inevitably will impact its key CHC brand and global No.1 Vicks – but the strong performance of the former Merck KGaA OTC products that P&G acquired in 2018, including various VMS brands (Neurobion, Seven Seas, etc) which produced growth in the “high teens” in Q4, point to the importance of a strong portfolio mix.

In its January 2021 investor presentation, Swiss-based Galenica said it has slightly exceeded its sales guidance (+2-5%), generating a 5.4% rise in net sales in 2020 to CHF3.5bn (US$4bn). Health & Beauty recorded net sales of CHF1.7bn (US$1.9bn, +3.1%); Retail accounted for CHF1.5bn (US$1.7bn, +2.7%); and Products & Brands CHF111.7mn (US$126mn, +9.4%). Cold, beauty, travel-related and ibuprofen products were very negatively impacted by Covid-19, with additional sales from hygiene and prevention products only partially compensating for this. Growth was driven by expansion activities such as acquisitions in the pharmacy network and product portfolio. In its facts & figures for 2020 (see below), Galenica pointed to several CHC trends, such as the sharp decline of cough products and the rise of antiseptics & disinfectants like Septo Clean.

_{Source: Galenica}

According to an unaudited trading update for the year ended 31st December 2020, UK-based Alliance Pharma said that “see-through” revenues (including underlying sales from Nizoral anti-dandruff shampoo) for 2020 were down 5% on the prior year at £137.5mn (US$188mn), both on a reported and constant currency basis. The company noted this reflects the impact of Covid-19. Consumer Healthcare revenues were up 1% to £93.0mn (US$127mn). Scar treatment Kelo-cote revenues rose by 12% to £34.7mn (US$47mn) and Nizoral was 4% ahead at £21.0mn (US$29mn). The recent acquisition of US-based Biogix, which brought Amberen – a fast-growing brand for the relief of menopause symptoms – into the group, is expected to be earnings-enhancing in FY 2021 and significantly earnings-enhancing from FY 2022.

Alliance Pharma CEO, Peter Butterfield, said: “The group continued to deliver a robust operational and financial performance in H2 2020, despite the ongoing challenges of the pandemic. While topline revenue growth has been constrained overall, our Consumer Healthcare business has performed well given the market backdrop and we have seen some strong performances from a number of our brands, in particular Kelo-cote.”

We have just announced a full schedule of webinars to take you through 2021. Exploring a range of trends and issues impacting the industry, we are kicking off with regional overviews of the Sleep, Memory & Mood markets. You can sign up for either the Asia-Pacific Hot Topic Webinar on 24 February, or the North America & Latin America Hot Topic Webinar on 3 March. Find out about the rest of our online events for 2021, by contacting elizabeth.bernos@NicholasHall.com.